In men with a clinical diagnosis of benign prostatic hyperplasia (BPH), polytomous logistic regression analysis was conducted to evaluate associations between two silent polymorphisms in SRD5A1 (codon positions 30 and 116), two polymorphisms in SRD5A2 (Val89Leu substitution and C to T transition in intron 1), a trinucleotide (CAG) n repeat in androgen receptor (AR), and an Arg492Cys substitution in ADRA1A and clinical parameters that characterize severity of BPH. Candidate gene selection was based on two mechanistic pathways targeted by pharmacotherapy for BPH: (1) androgen metabolic loci contributing to prostate growth (static obstruction); and (2) factors affecting smooth muscle tone (dynamic obstruction). Polymorphisms in SRD5A2 were not associated with severity of BPH; however, SRD5A1 polymorphisms were associated with severity of BPH. The process(es) in which these silent single-nucleotide polymorphisms (SNPs) influence BPH phenotypes is unknown and additional studies will be needed to assess whether these SNPs have direct functional consequences. The characterization of additional molecular factors that contribute to static and dynamic obstruction may help predict response to pharmacotherapy and serve to identify novel drug targets for the clinical management of BPH.
INTRODUCTION
Benign prostatic hyperplasia (BPH) is an extremely common condition among aging men that typically manifests as a constellation of lower urinary tract symptoms (LUTS) which are bothersome, impair psychological and functional well-being, and interfere with activities of daily living. Prevalence estimates for BPH vary, but it is clear that BPH is nearly ubiquitous in older men and is a significant health concern.
1 Histologic evidence of BPH was found in almost 90% of men in their 80s, 2 and it is estimated that nearly one in four men receive treatment for LUTS by the eighth decade of life. 3 Despite significant morbidity caused by BPH, the etiology and determinants of severity of this condition remain poorly understood.
The current BPH literature suggests that LUTS generally result from static (mechanical) and/or dynamic component(s). The static component is a consequence of the benign enlargement of the prostate, which increases pressure on the urethra with subsequent obstruction of urine flow. Prostate growth is regulated, in part, by a defined androgendependent pathway, 4 which begins with the diffusion of serum testosterone (TES) into the prostate. In the prostatic stroma, TES is irreversibly converted to the more active dihydrotestosterone (DHT) by the enzyme 5a-reductase type II. Converted DHT then enters epithelial cells and selectively binds to the androgen receptor (AR), a ligand-dependent transcription factor, forming a DHT/AR complex. This complex is translocated into the nucleus and promotes prostatic growth by binding to androgen response elements in the regulatory region of target genes 5, 6 (eg, androgen regulation of prostate-specific antigen (PSA) expression is mediated by AR). 7 By contrast, dynamic obstruction is caused by dysfunction of smooth muscle tone in the prostatic capsule surrounding the prostate. Prostatic smooth muscle tone varies according to the sympathetic stimulation of a 1 -adrenoceptors, in particular, the a 1A -adrenoceptor subtype. [8] [9] [10] In a healthy male, smooth muscle in the capsule contracts to propel prostatic secretions from storage into the prostatic urethra during ejaculation. In a BPH disease state, increased smooth muscle tone in the outer prostatic capsule is believed to bring on LUTS by increasing urethral resistance. Consequently, the dynamic component of BPH is determined, at least partially, by a 1A -adrenoceptor activity and prostatic smooth muscle tone. 11 Systematic screens of genes encoding for 5a-reductase type I and II (SRD5A1 and SRD5A2), AR, and a 1A -adrenoceptor (ADRA1A) have identified polymorphisms that may influence protein production and/or integrity. These polymorphic loci can be operationally compartmentalized into one of two pathways that contribute to the severity of BPH: (1) an androgen-dependent pathway, involving 5a-reductase and AR activity, contributing to static obstruction; and (2) a non-growth-dependent pathway, mediated by a 1A -adrenoceptor, that may be instrumental in the onset of dynamic obstruction. The polymorphisms evaluated in this study included two silent polymorphisms in SRD5A1 (codon positions 30 and 116), 12 two polymorphisms in SRD5A2 (Val89Leu 13, 14 and C to T transition in intron 1), a (CAG) n repeat in AR, 15, 16 and Arg492Cys substitution in ADRA1A.
17,18
Pharmacotherapy with a-blockers and 5a-reductase inhibitors has become commonplace for the medical management of BPH. 19 Alpha blockers alleviate dynamic obstruction by interrupting motor sympathetic adrenergic nerve stimulation in the prostate, 20 while 5a-reductase inhibitors limit DHT production resulting in involution of the prostate. 21 Given the importance of a-blockers and 5a-reductase inhibitors in the treatment of BPH, this study was undertaken to evaluate associations between polymorphisms in candidate genes whose effects are targeted by pharmacotherapy and clinical parameters used to characterize the severity of BPH. Further characterization of polymorphic loci hypothesized to play a role in static and dynamic obstruction precipitated by BPH may help to shed light on etiologic mechanisms predisposing men to BPH.
RESULTS

Baseline Distributions
Genetic data were available for 87% of the study participants (n ¼ 2428 out of 2802) for whom baseline data were available (Table 1) . Genotypes were missing primarily because of failed assays or subject refusal to submit a blood sample for genetic analysis. The baseline characteristics for the subset of men in whom genetic data were unavailable appeared similar to those of the study group as a whole (data not shown). Table 3 . Polymorphisms in 5a-reductase type II (SRD5A2) did not appear to be associated with the severity of BPH; however, polymorphisms in 5a-reductase type I were associated with severity.
The silent Arg30 polymorphism in 5a-reductase type I (SRD5A1) was associated with serum TES and DHT levels (P ¼ 0.03 and P ¼ 0.04, respectively), and there was limited evidence for an association with maximum urinary flow (Q max ; P ¼ 0.09), and post-void residual volume (PVR; P ¼ 0.10) ( Table 3 ). Further evaluation of category-specific estimates (ie, pair-wise genotype comparisons) revealed an association between the predominant SRD5A1 Arg30-G/G genotype and a less severe BPH disease state (model fit shown in Figure 1 ). In comparison to predominant homozygotes (Arg30-G/G), the probabilities of the Arg30-G/C and Arg30-C/C genotypes were higher at higher levels of TES (P ¼ 0.04 and P ¼ 0.01, respectively) and DHT (P ¼ 0.02 and Not clinically significant; mean values were comparable across C/C, C/T, and T/T genotypes (10.273.6, 10.373.3, 11.074.2, respectively). e (CAG) n categorized as p18, 18-23, and X23 repeats.
Evaluation of candidate genes for severity of BPH M Klotsman et al P ¼ 0.03, respectively). A ratio of TES to DHT was also analyzed to further assess whether SRD5A1 polymorphisms affect androgen metabolism, but no associations were detected. Additionally, pair-wise comparisons between the two homozygous groups showed that the Arg30-G/G genotype was associated with slightly faster maximum urinary flow (P ¼ 0.05) and a small decrease in post-void residual volume (P ¼ 0.04) (Figure 1 ). Further analysis did not identify associations between the joint distribution of clinical predictors and SRD5A1 Arg30 genotypes.
The Ala116 SNP was associated with maximum urine flow (P ¼ 0.04) and post-void residual volume (P ¼ 0.01). Plotting the fitted genotype probabilities of Ala116 against Q max and PVR revealed a trend similar to that observed for Arg30 (which is in partial LD with Ala116); the homozygous variant Ala116-G/G differed from predominant homozygotes and heterozygotes with respect to Q max and PVR (pairwise Ala116 ÀA/A vs ÀG/G comparisons P ¼ 0.01 and P ¼ 0.003, respectively).
Complex associations between AR (CAG) repeats and serum androgen levels were observed. Associations were not observed among men less than 60 years of age, while genotype/phenotype associations were identified among older men (Figure 2 ). Comparing men with long-repeat lengths ((CAG) X23 ) to those with medium length repeats ((CAG) [19] [20] [21] [22] [23] ) showed the probability of (CAG) X23 to be strongly associated with high serum TES levels (P ¼ 0.004), but less so with elevated DHT levels (P ¼ 0.01). Results for men with short repeat lengths ((CAG) o19 ) were difficult to interpret because of the limited sample size (n ¼ 83). Similar results were obtained using a dichotomous (CAG) classification scheme encountered in the literature; 22 longer repeats (CAG422 repeats) were associated with elevated TES and DHT levels (P ¼ 0.003 and P ¼ 0.01, respectively).
An SNP in the a 1A -adrenergic receptor was evaluated because the product of this gene is hypothesized to contribute to dynamic obstruction. While not on the androgen pathway, a weak association between a 1A -adrenergic receptor Arg492Cys polymorphism and DHT was found (P ¼ 0.05); however, this association did not persist (P ¼ 0.15) after excluding an outlier with serum DHT concentration of 4210 ng/ml. Evaluation of the other clinical predictor variables did not identify outliers. Spline regression analysis, performed to more thoroughly examine potential doseresponse relationships, did not improve the fit to the data of any of the models considered. 
DISCUSSION
The notion that lower urinary tract symptoms arise from either a static or dynamic component is supported by a growing body of BPH literature and clinical experience; yet, the molecular epidemiologic evidence supporting either of these pathways is scant. To improve the understanding of molecular factors contributing to this condition, associations between candidate gene loci and severity of BPH were evaluated. Candidate gene selection was based on mechanistic pathways that provide a plausible etiology for the involvement of androgen metabolic loci contributing to prostate growth (static obstruction) and genes encoding for factors affecting smooth muscle tone (dynamic obstruction).
We evaluated the association between severity of BPH and polymorphisms in SRD5A1 and SRD5A2, two genes involved in the conversion of TES to DHT. As DHT is evidently a more active prostate mitogen 23 with greater affinity for the AR, genetic factors that could affect 5a-reductase expression or activity were hypothesized to be associated with the severity of BPH. As previously reported, 24 the frequency of the SRD5A2-Val89Leu polymorphism shows marked differences among ethnic groups; however, the phenotypic consequences associated with this SNP are uncertain. In vitro studies have shown that the predominant 89-Val/Val is over 30% more active than variant 89-Leu/Leu. 25, 26 Observational studies have examined the risk of prostate cancer associated with the Val89Leu SNP, but results have varied 14, 24, [27] [28] [29] and no conclusive genotype/phenotype associations can be drawn. In the present study, we did not find associations between SRD5A2 polymorphisms and severity of BPH. Based on these findings and previous studies examining this SNP, we conclude that the Val89Leu SNP plays, at most, a minimal role in the natural history of BPH. Further study of additional SRD5A2 polymorphisms (eg, a functional SNP at codon 49) 27, 30 is needed to rule out SRD5A2 as a genetic determinant of BPH severity.
SRD5A1 has not been extensively studied in relation to BPH because SRD5A2 is the predominant isozyme found in the prostate. 31 Studies have shown SRD5A1 expression levels to be elevated in BPH tissue, 32 but associations between SRD5A1 polymorphisms and BPH have not been reported. We identified associations between severity of BPH (though not for prostate volume) and a silent polymorphism in SRD5A1 at codon 30, thus further implicating SRD5A1 in BPH. Specifically, the variant Arg30 allele was associated with higher serum androgen concentrations, impaired Q max , and increased post-void urinary retention volume. Also, a silent polymorphism at codon 116 was associated with Q max Figure 2 Associations between serum androgen levels and AR (CAG) n repeat length. The probability of (CAG) length in relation to serum TES and serum DHT among Caucasian subjects 60 years and younger (panels a and b, respectively) and Caucasian subjects older than 60 years (panels c and d, respectively).
Evaluation of candidate genes for severity of BPH M Klotsman et al and PVR. The process(es) in which these silent SNPs influences BPH phenotypes is unknown and additional studies will be needed to assess whether these SNPs have direct functional consequences (ie, altered expression levels, reduced protein activity). One likely explanation is that the silent SRD5A1 SNPs are in LD with undefined causative allele(s). Alternatively, it is plausible that the silent SNPs impact upon the rate of translation, thus affecting the conversion of DHT to TES in the liver. Verifying the involvement of SRD5A1 in the clinical phenotype of BPH would reinforce the rationale behind the use of dual 5a-reductase inhibitors for the treatment of this condition.
For their activity to manifest in the prostate, androgens must first bind to the AR and form an AR-androgen complex that acts to transduce growth signals from the cellular environment to the nucleus. Given the importance of AR in the modulation of genes involved in cell proliferation and differentiation, the (CAG) n microsatellite has been intensely studied, in particular with respect to prostate cancer. 22 Both in vitro and in vivo studies have demonstrated that CAG repeat length is inversely related to transactivation activity of AR, [33] [34] [35] [36] with additional evidence implicating AR in BPH severity coming from population-based observational studies. Using data from the Physicians' Health Study, it was determined that the risk of surgery for BPH increased linearly with decreasing CAG repeat length (OR ¼ 1.76, 95% CI (1.2, 2.7) for men with (CAG) p19 relative to men with (CAG) X25 ). 37 Similar results were obtained in the Health Professionals Follow-Up Study cohort, which used a similar (CAG) classification scheme; the odds ratio for BPH surgery or an enlarged prostate was 1.92 (95% CI 1.2, 3.0). 15 Also, the prevalence of BPH increased with age and shorter CAG repeat lengths, leading the authors of this study to conclude that variability in CAG length influences the development of symptomatic BPH. A third study, conducted among Japanese prostatectomy patients (176 BPH cases and 41 controls), modeled resected prostate weight against CAG repeat length. Using this methodology, a statistically significant trend for larger adenoma size with short CAG repeat length was identified, leading these authors to postulate that shorter CAG alleles represent a genetic risk factor that promotes the growth of BPH. 16 In contrast to the observational studies described above, direct associations between candidate gene loci and risk of BPH were not evaluated in the present study because a suitable control population was unavailable. Rather, an application of logistic regression modeling, which under general conditions yields maximum likelihood estimates that are consistent, asymptomatically efficient, and asymptomatically normal, was used to identify associations between genetic loci and clinical measures marking the severity of BPH. Using this analytic approach, longer (CAG) repeats were found to be associated with elevated androgen levels. The higher probability of observing long (CAG) repeats at higher serum androgen levels may represent a systemic response to decreased AR activity associated with longer (CAG) repeats (ie, increased androgen bioavailability to counteract reduced AR activity).
The lack of a consensus definition for BPH is a significant hindrance to the epidemiologic study of BPH. Neither the clinical measures that should be used to describe the properties of BPH, nor the normal ranges for these measures have been agreed upon. The analytic approach used circumvented this problem by using continuous clinical predictor variables to assess genotype/phenotype associations. While it was not possible to identify disease susceptibility loci, for example by comparing non-symptomatic men with those that have BPH, this study identified genetic factors that may play a role in the severity of BPH among a symptomatic population. Multiple testing, which can inflate the type I error rate and lead to spurious findings, is another potential limitation. While it is plausible that the associations identified for polymorphisms in SRD5A1 and AR are false positives, we feel this to be unlikely given that genotype/phenotype associations held across multiple phenotypes (eg, the silent Arg30 SNP was associated with higher serum androgen concentrations, impaired Q max , and increased post-void urinary retention volume).
Overall, our results, taken together with previous reports, demonstrate that the molecular determinants of BPH severity are complex. Further studies are needed to more clearly define prostatic growth pathways and to identify factors that increase smooth muscle tone in the prostatic capsule. The characterization of additional molecular factors that contribute to static and dynamic obstruction may serve to identify novel drug targets for the clinical management of BPH.
METHODS
Study Population
Baseline data were available for 2802 men diagnosed with moderate-to-severe benign prostatic hyperplasia recruited throughout the United States to participate in randomized, placebo-controlled clinical trials. These trials, previously described in detail, 38 had identical inclusion and exclusion criteria to allow for a preplanned pooled analysis of the data. Briefly, to be eligible for inclusion, participants had to be at least 50 years of age, have a minimum American Urologic Association symptom index (AUA-SI) score of 12, a prostate volume 430 cm 3 , and maximum urinary flow rates of less than 15 ml/s. Participants were excluded from the study if they had ever used 5a-reductase inhibitors or alpha-receptor blockers within 4 weeks of screening. Prior to study enrollment, the aims of the study were fully explained and informed consent was obtained from each participant. The study protocol was reviewed and approved by the appropriate Institutional Review Boards.
Ascertainment of Clinical Predictor Variables
Demographic and clinical severity indicators for BPH and its complications were collected for each subject according to a standardized protocol. All statistical analysis was performed on baseline measures collected among Caucasians prior to receiving placebo or experimental drug.
Subjects' total prostate volume (TPV) and transition zone volume (TZV) were measured by transrectal ultrasound Evaluation of candidate genes for severity of BPH M Klotsman et al (TRUS), an established method of measuring prostate size that has a high level of reproducibility for volume measurements. 39, 40 The anteroposterior, cephalocaudal, and transverse diameters of the prostate were obtained to calculate the prostate volume using the following formula: pC6(anteroposterior Â cephalocaudal Â transverse). The TZV was measured because this region is more prone to hyperplasia and more directly impinges on the prostatic urethra. Pressure-flow studies were performed to provide information on urethral resistance, bladder capacity, residual urine volume, and urinary flow rate. The peak urine flow (Q max ) was measured using a Dantec Uroflow Meter (URODYN 1000) with a Thompson filter (a minimum voided volume of 4125 ml was required to qualify the measurement). Subjects' post-void residual volume was measured suprapubically by an ultrasound immediately after every urinary flow measurement.
Ascertainment of Clinical laboratory Tests
Blood samples were collected for each participant. All hematological and biochemical measurements, including PSA, TES, and DHT, were conducted by a central laboratory in a blinded manner.
Genotyping
All genotyping was based on whole blood collected from subjects who consented to genetic testing. DNA extraction was performed using the Puregene DNA isolation kit at a central laboratory (LabCorp, Research Triangle Park, NC, USA). Subjects were tested for a total of five SNPs and one trinucleotide repeat. Polymorphisms evaluated include: a C to T transition in intron 1 (C to T) and a Val to Leu substitution at amino-acid position 89 (Val89Leu) in 5-alpha reductase type II 41 (HUGO nomenclature: steroid-5-alphareductase, alpha polypeptide 2, SRD5A2; Sequence Accession ID: NM_000348); two silent SNPs in 5-alpha reductase type I(12) (HUGO nomenclature: steroid-5-alpha-reductase, alpha polypeptide 1, SRD5A1; Sequence Accession ID: NM_001047) at codons 30 (Arg30) and 116 (Ala116); an Arg to Cys substitution at codon 492 in a 1A -adrenergic receptor 42 (OMIM nomenclature: Alpha-1A-adrenergic receptor, ADRA1A; OMIM access number: 104221); and a (CAG) n repeat in the AR 43 (HUGO nomenclature: AR; Sequence Accession ID: M20132). For presentation purposes, the more frequently observed allele at each locus is referred to as the 'predominant' allele, while 'variant' refers to the less commonly observed allele.
All SNPs were analyzed in a blinded manner by validated PCR-RFLP procedures at a central laboratory (GlaxoWellcome Inc., Research Triangle Park, NC, USA). PCR for all genotyping was performed in 96-well specimen plates with negative controls (no template DNA) and positive controls (DNAs of known genotype). Approximately 5 ml PCR product was used for each subsequent enzyme digestion. The SRD5A2 Val89Leu polymorphism and C to T transition were recognized by the restriction enzymes SunI and PstI, respectively. The SRD5A1 silent Arg30 polymorphism, a G to C transition in exon 1, was recognized by HinfI. 12 The SRD5A1 silent Ala116 polymorphism, a A to G transition in exon 2, was recognized by NspI. 12 The Arg492Cys polymorphism in a 1A -adrenergic receptor was characterized by digestion with PstI. Results were visually obtained by evaluating 3% agarose gels. (CAG) n repeat length in AR was established by direct sequencing at a central laboratory (GlaxoWellcome Inc., Research Triangle Park). Genotypes were entered into the database independently by two individuals.
Analysis
Allele frequencies were estimated by allele counting. Departures from Hardy-Weinberg equilibrium (HWE) were assessed by a w 2 goodness-of-fit test based on the difference between expected (calculated from the allele frequencies) and observed genotype frequencies. All genetic analyses were performed using the HelixTree software package (Golden Helix, Bozeman, Montana).
The strict study eligibility criteria yielded a study group consisting of only BPH patients. Consequently, a case-only analysis was appropriate for assessing etiologic gene-by-gene interaction. 44 Here we define the interaction on a multiplicative scale, considering that interaction is present between two unlinked genes if there is departure from equality of the genotype relative risks at one locus across genotypes at the other locus. We considered gene-by-gene interaction of all pairs of unlinked genes lying on the same androgen-dependent prostatic growth pathway by constructing a series of genotype-by-genotype tables (three by three contingency tables) and testing the independence. 45 An overall w 2 (d.f. ¼ 4) was calculated for each pair to test the null hypothesis that the joint effects were multiplicative (statistical significance was two-tailed and defined as Po0.05). Similar to the single-locus test described by Nielsen et al, 46 this is a valid test for interaction in the absence of population LD. A hallmark of many genetic-based disorders is an earlier age of onset (eg, the occurrence of cancer at an unusually young age, relative to the typical age for the type of cancer, is suggestive of an inherited predisposition). 47 Accordingly, this analysis was repeated for men less than 60 years old to consider whether gene-by-gene interaction contributed to risk of BPH.
Polytomous logistic regression analysis was conducted to evaluate associations between genotypes and clinical parameters used to characterize the severity of BPH. The probability of observing a locus-specific genotype was estimated by polytomous logistic regression, based on selecting values for the model parameters that maximize the likelihood of the observed data. Thus, we modeled Pr (genotype ¼ i|CP 1 , CP 2 , y, CP N ) where i indexes the genotype and the CP n are clinical predictor variables. In applying the logistic model in this manner, overall two degrees-of-freedom w 2 tests can be used to assess associations between clinical variables and the three-level genotypes corresponding to the bi-allelic candidate polymorphic loci (predominant homozygotes, heterozygotes, and variant homozygotes). The likelihood ratio test for a given clinical measure is based on comparing the fit of such a model with that of a model with all the same clinical predictors except the one being tested. Based on this w 2 test, the P-value quantifies the strength of the evidence for an association between the genotype and the clinical predictor, adjusting for the values of the other clinical predictors.
Initially, polytomous-outcome logistic regression models were constructed by modeling the three-category genotype at each locus against each continuous clinical predictor to separately maximize each likelihood. If the predictive contribution of a given clinical predictor, CP n , approached statistical significance (Po0.10), then category-specific parameters were estimated to explore which contrasts (ie, pair-wise contrasts between genotype groups; d.f. ¼ 1) were producing the apparent effect. These pair-wise comparisons (predominant homozygotes vs heterozygotes and variant homozygotes) were made by evaluating pair-specific w 2 statistics and corresponding P-values (ie, test statistics corresponding to the specific genotype category pair) to test the null hypothesis that the relative frequencies of genotype ¼ i vs genotype ¼ i 0 are the same over the observed range of the given clinical explanatory variable, CP n . In other words, a significant test (defined as Po0.05) indicates that CP n is related to the relative genotype frequencies Pr(genotype ¼ i), suggesting the presence of a phenotype/ genotype association. Violations of constancy of genotype probabilities were visualized by plotting the estimated predicted probability of genotype ¼ i against each predictor.
To further characterize potential dose-response relationships between genotypes and predictors, those variables that appeared to be associated with genotype were also modeled using quadratic splines. 48 Splines were constructed by introducing knots at the 25th and 75th percentiles of the CP distribution. Model fit was assessed by using a likelihood ratio test to compare spline models to those with a logisticlinear structure.
Step-up modeling, based on the initial logistic models fit, was used to evaluate whether the fit to the data was improved by including more of the clinical variables as predictors. Models fit with multiple predictor variables were compared to the reduced models by likelihood ratio tests. All analyses were performed using the SAS and JMP statistical software packages (SAS Institute, Cary, NC, USA).
DUALITY OF INTEREST
Drs M Klotsman, K Davis, and CG Binnie are employees of GlaxoSmithKline.
